^
    2years
    An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects (clinicaltrials.gov)
    P1, N=18, Recruiting, Shenzhen Fifth People's Hospital
    New P1 trial • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HEC-016